GlobalData on MSN13h
Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trialShionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.
Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback